However, the information provided by nodal status is currently not being completely ignored when selecting postoperative treatment for younger patients, and the absence of the pathological information acquired from SLNB might still create challenges in the management of ER-positive ERBB2-negative BC. This evidence concerns the gene ERBB2 and breast cancer.